Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other financing activities (2016 - 2019)

Historic Other financing activities for Sangamo Therapeutics (SGMO) over the last 7 years, with Q1 2019 value amounting to $216000.0.

  • Sangamo Therapeutics' Other financing activities fell 9795.92% to $216000.0 in Q1 2019 from the same period last year, while for Sep 2021 it was $216000.0, marking a year-over-year decrease of 9916.37%. This contributed to the annual value of $943000.0 for FY2021, which is N/A changed from last year.
  • Latest data reveals that Sangamo Therapeutics reported Other financing activities of $216000.0 as of Q1 2019, which was down 9795.92% from $10.6 million recorded in Q1 2018.
  • Sangamo Therapeutics' Other financing activities' 5-year high stood at $15.0 million during Q4 2017, with a 5-year trough of -$1.0 million in Q4 2016.
  • Its 4-year average for Other financing activities is $6.2 million, with a median of $5.4 million in 2018.
  • As far as peak fluctuations go, Sangamo Therapeutics' Other financing activities soared by 158059.11% in 2017, and later tumbled by 9795.92% in 2019.
  • Sangamo Therapeutics' Other financing activities (Quarter) stood at -$1.0 million in 2016, then surged by 1580.59% to $15.0 million in 2017, then decreased by 29.57% to $10.6 million in 2018, then tumbled by 97.96% to $216000.0 in 2019.
  • Its last three reported values are $216000.0 in Q1 2019, $10.6 million for Q1 2018, and $15.0 million during Q4 2017.